These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 26032650)

  • 1. Performance of biopsy factors in predicting unfavorable disease in patients eligible for active surveillance according to the PRIAS criteria.
    Russo GI; Castelli T; Favilla V; Reale G; Urzì D; Privitera S; Fragalà E; Cimino S; Morgia G
    Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):338-42. PubMed ID: 26032650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Percentage of cancer involvement in positive cores can predict unfavorable disease in men with low-risk prostate cancer but eligible for the prostate cancer international: active surveillance criteria.
    Russo GI; Cimino S; Castelli T; Favilla V; Urzì D; Veroux M; Madonia M; Morgia G
    Urol Oncol; 2014 Apr; 32(3):291-6. PubMed ID: 24184119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does cumulative prostate cancer length (CCL) in prostate biopsies improve prediction of clinically insignificant cancer at radical prostatectomy in patients eligible for active surveillance?
    Chen DJ; Falzarano SM; McKenney JK; Przybycin CG; Reynolds JP; Roma A; Jones JS; Stephenson A; Klein E; Magi-Galluzzi C
    BJU Int; 2015 Aug; 116(2):220-9. PubMed ID: 25060664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PHI and PCA3 improve the prognostic performance of PRIAS and Epstein criteria in predicting insignificant prostate cancer in men eligible for active surveillance.
    Cantiello F; Russo GI; Cicione A; Ferro M; Cimino S; Favilla V; Perdonà S; De Cobelli O; Magno C; Morgia G; Damiano R
    World J Urol; 2016 Apr; 34(4):485-93. PubMed ID: 26194612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended biopsy based criteria incorporating cumulative cancer length for predicting clinically insignificant prostate cancer.
    Komai Y; Kawakami S; Numao N; Fujii Y; Saito K; Kubo Y; Koga F; Kumagai J; Yamamoto S; Yonese J; Ishikawa Y; Fukui I; Kihara K
    BJU Int; 2012 Dec; 110(11 Pt B):E564-9. PubMed ID: 22757686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS).
    El Hajj A; Ploussard G; de la Taille A; Allory Y; Vordos D; Hoznek A; Abbou CC; Salomon L
    BJU Int; 2013 Jan; 111(1):53-9. PubMed ID: 22726582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detailed biopsy pathologic features as predictive factors for initial reclassification in prostate cancer patients eligible for active surveillance.
    Ploussard G; de la Taille A; Terry S; Allory Y; Ouzaïd I; Vacherot F; Abbou CC; Salomon L
    Urol Oncol; 2013 Oct; 31(7):1060-6. PubMed ID: 22300755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The biopsy Gleason score 3+4 in a single core does not necessarily reflect an unfavourable pathological disease after radical prostatectomy in comparison with biopsy Gleason score 3+3: looking for larger selection criteria for active surveillance candidates.
    Schiavina R; Borghesi M; Brunocilla E; Romagnoli D; Diazzi D; Giunchi F; Vagnoni V; Pultrone CV; Dababneh H; Porreca A; Fiorentino M; Martorana G
    Prostate Cancer Prostatic Dis; 2015 Sep; 18(3):270-5. PubMed ID: 26055663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
    Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?
    Jin BS; Kang SH; Kim DY; Oh HG; Kim CI; Moon GH; Kwon TG; Park JS
    Korean J Urol; 2015 Sep; 56(9):624-9. PubMed ID: 26366274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
    Bokhorst LP; Valdagni R; Rannikko A; Kakehi Y; Pickles T; Bangma CH; Roobol MJ;
    Eur Urol; 2016 Dec; 70(6):954-960. PubMed ID: 27329565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter analysis of pathological outcomes of patients eligible for active surveillance according to PRIAS criteria.
    Grasso AA; Cozzi G; DE Lorenzis E; Ceruti C; Crivellaro S; Falsaperla M; Minervini A; Masieri L; Porreca A; Zaramella S; Rocco B
    Minerva Urol Nefrol; 2016 Jun; 68(3):237-41. PubMed ID: 25732225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols.
    Iremashvili V; Pelaez L; Manoharan M; Jorda M; Rosenberg DL; Soloway MS
    Eur Urol; 2012 Sep; 62(3):462-8. PubMed ID: 22445138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study.
    Bul M; Zhu X; Rannikko A; Staerman F; Valdagni R; Pickles T; Bangma CH; Roobol MJ
    Eur Urol; 2012 Aug; 62(2):195-200. PubMed ID: 22342775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria?
    Ploussard G; Salomon L; Xylinas E; Allory Y; Vordos D; Hoznek A; Abbou CC; de la Taille A
    J Urol; 2010 Feb; 183(2):539-44. PubMed ID: 20006888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How accurate is our clinical prediction of "minimal prostate cancer"?
    Leibovici D; Shikanov S; Gofrit ON; Zagaja GP; Shilo Y; Shalhav AL
    Isr Med Assoc J; 2013 Jul; 15(7):359-63. PubMed ID: 23943981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The number of cores at first biopsy may suggest the need for a confirmatory biopsy in patients eligible for active surveillance-implication for clinical decision making in the real-life setting.
    Villa L; Salonia A; Capitanio U; Scattoni V; Abdollah F; Suardi N; Dell'Oglio P; Freschi M; Montorsi F; Briganti A
    Urology; 2014 Sep; 84(3):634-41. PubMed ID: 25059594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
    Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
    BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary Gleason pattern upgrading in contemporary patients with D'Amico low-risk prostate cancer: implications for future biomarkers and imaging modalities.
    Leyh-Bannurah SR; Abou-Haidar H; Dell'Oglio P; Schiffmann J; Tian Z; Heinzer H; Huland H; Graefen M; Budäus L; Karakiewicz PI
    BJU Int; 2017 May; 119(5):692-699. PubMed ID: 27367469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.